Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122378608> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2122378608 endingPage "975" @default.
- W2122378608 startingPage "975" @default.
- W2122378608 abstract "Potential conflict of interest: Nothing to report. To the Editor: Mixed cryoglobulinemia (MC) vasculitis affects approximately 5% of individuals with chronic hepatitis C virus (HCV) infection and ranges from mild to life‐threatening.1 Sustained virological response leads to remission of vasculitis and reduced mortality, but the response rate to interferon‐based regimens is low for frequent intolerance and ineligibility.1 Interferon‐ineligible/intolerant/nonresponder patients with severe organ damage require salvage treatments with rituximab (RTX) or plasma exchange; however, these treatments are expensive and provide only temporary benefit.1 Both the American Association for the Study of Liver Diseases (http://www.hcvguidelines.org/full‐report/when‐and‐whom‐initiate‐hcv‐therapy) and the European Association for the Study of the Liver (http://www.easl.eu/_newsroom/latest‐news/easl‐recommendations‐on‐treatment‐of‐hepatitis‐c‐2014) recommend prioritizing anti‐HCV treatment in patients with MC vasculitis, but the impact of the severity of vasculitis on indication for early treatment is not thoroughly addressed. We performed a retrospective chart review of 58 patients with HCV‐associated MC vasculitis followed at our institution (Supporting Methods). Interferon‐based therapy led to sustained virological response in 11 patients (19%) (Supporting Fig. S1). Vasculitis was stratified into mild/moderate (purpura, peripheral neuropathy) and severe (nephropathy, chronic skin ulcers). Thirty interferon‐ineligible/intolerant/nonresponder patients with chronic hepatitis, stable through follow‐up, were selected; eight of them had severe vasculitis and 22 mild/moderate vasculitis (Supporting Fig. S1). The healthcare history, costs, and outcomes were compared in these two groups (Table 1); only hospitalizations and treatments related to complications of vasculitis were considered. Patients with severe vasculitis stayed in hospital a mean of 16.59 days/year and were all treated with RTX, plasma exchange, or both. Two of eight patients with severe vasculitis died from its complications, one from intestinal vasculitis and one from end‐stage renal disease and systemic infection resulting from infected skin ulcers. Patients with mild/moderate vasculitis stayed in hospital 0.66 days/year; only two of 22 were treated with RTX, and none died. Thus, healthcare cost overall and risk of death were higher in patients with severe MC compared to those with mild/moderate disease. Furthermore, there did not appear to be an association of use of either plasma exchange or RTX with cost (Supporting Table S1), which may have been related more to severity of illness than to response to treatment. Table 1 - Health Care History of Interferon‐Ineligible/Intolerant or Nonresponder Patients With Chronic Hepatitis C and Cryoglobulinemic Vasculitis Vasculitis Number of Patients Sex (F/M) Age, Median (Range) Mean Follow‐up (Years) Mean Days in Hospital/Year Mean Hospitalization Episodes/Year Treatments (Number of Patients) Mean Healthcare Cost/Year (US $) Deaths Severe 8 7/1 66 (50‐81) 4.24 16.59 0.89 RTX 3 PE 3 RTX/PE 2 11,229 2 Mild/moderate 22 16/6 68 (51‐77) 5.3 0.66 0.08 RTX 2 PE 0 RTX/PE 0 815 0 Healthcare costs include only those for hospitalizations and for RTX and PE treatments.Abbreviations: RTX, rituximab; PE, plasma exchange. Hagan et al.3 surmise a 12‐week treatment with sofosbuvir/simeprevir, at a drug cost of $150,000, as the state‐of‐the‐art, most cost‐effective therapy for interferon‐ineligible/intolerant HCV‐infected individuals. Given the relatively high cost of care and the poor response/high risk of death in patients with severe MC, prioritization of these patients for treatment with interferon‐free therapy should be considered; and studies to determine tolerability and efficacy are warranted." @default.
- W2122378608 created "2016-06-24" @default.
- W2122378608 creator A5013897699 @default.
- W2122378608 creator A5032466668 @default.
- W2122378608 creator A5040522334 @default.
- W2122378608 creator A5054791712 @default.
- W2122378608 creator A5055028093 @default.
- W2122378608 creator A5084594597 @default.
- W2122378608 date "2015-02-17" @default.
- W2122378608 modified "2023-09-27" @default.
- W2122378608 title "The case for cost‐effectively treating cryoglobulinemic vasculitis with interferon‐free anti–hepatitis C virus therapy" @default.
- W2122378608 cites W2008646009 @default.
- W2122378608 cites W2044713055 @default.
- W2122378608 cites W2064650635 @default.
- W2122378608 doi "https://doi.org/10.1002/hep.27600" @default.
- W2122378608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25380535" @default.
- W2122378608 hasPublicationYear "2015" @default.
- W2122378608 type Work @default.
- W2122378608 sameAs 2122378608 @default.
- W2122378608 citedByCount "3" @default.
- W2122378608 countsByYear W21223786082016 @default.
- W2122378608 countsByYear W21223786082017 @default.
- W2122378608 crossrefType "journal-article" @default.
- W2122378608 hasAuthorship W2122378608A5013897699 @default.
- W2122378608 hasAuthorship W2122378608A5032466668 @default.
- W2122378608 hasAuthorship W2122378608A5040522334 @default.
- W2122378608 hasAuthorship W2122378608A5054791712 @default.
- W2122378608 hasAuthorship W2122378608A5055028093 @default.
- W2122378608 hasAuthorship W2122378608A5084594597 @default.
- W2122378608 hasBestOaLocation W21223786081 @default.
- W2122378608 hasConcept C126322002 @default.
- W2122378608 hasConcept C203014093 @default.
- W2122378608 hasConcept C2522874641 @default.
- W2122378608 hasConcept C2776015282 @default.
- W2122378608 hasConcept C2776178377 @default.
- W2122378608 hasConcept C2776408679 @default.
- W2122378608 hasConcept C2776455275 @default.
- W2122378608 hasConcept C2778585876 @default.
- W2122378608 hasConcept C2778922544 @default.
- W2122378608 hasConcept C2779134260 @default.
- W2122378608 hasConcept C2779338263 @default.
- W2122378608 hasConcept C2780653079 @default.
- W2122378608 hasConcept C2909179924 @default.
- W2122378608 hasConcept C71924100 @default.
- W2122378608 hasConcept C89560881 @default.
- W2122378608 hasConcept C90924648 @default.
- W2122378608 hasConceptScore W2122378608C126322002 @default.
- W2122378608 hasConceptScore W2122378608C203014093 @default.
- W2122378608 hasConceptScore W2122378608C2522874641 @default.
- W2122378608 hasConceptScore W2122378608C2776015282 @default.
- W2122378608 hasConceptScore W2122378608C2776178377 @default.
- W2122378608 hasConceptScore W2122378608C2776408679 @default.
- W2122378608 hasConceptScore W2122378608C2776455275 @default.
- W2122378608 hasConceptScore W2122378608C2778585876 @default.
- W2122378608 hasConceptScore W2122378608C2778922544 @default.
- W2122378608 hasConceptScore W2122378608C2779134260 @default.
- W2122378608 hasConceptScore W2122378608C2779338263 @default.
- W2122378608 hasConceptScore W2122378608C2780653079 @default.
- W2122378608 hasConceptScore W2122378608C2909179924 @default.
- W2122378608 hasConceptScore W2122378608C71924100 @default.
- W2122378608 hasConceptScore W2122378608C89560881 @default.
- W2122378608 hasConceptScore W2122378608C90924648 @default.
- W2122378608 hasIssue "3" @default.
- W2122378608 hasLocation W21223786081 @default.
- W2122378608 hasLocation W21223786082 @default.
- W2122378608 hasLocation W21223786083 @default.
- W2122378608 hasOpenAccess W2122378608 @default.
- W2122378608 hasPrimaryLocation W21223786081 @default.
- W2122378608 hasRelatedWork W115156286 @default.
- W2122378608 hasRelatedWork W1983621878 @default.
- W2122378608 hasRelatedWork W2018288904 @default.
- W2122378608 hasRelatedWork W2035777161 @default.
- W2122378608 hasRelatedWork W2061912547 @default.
- W2122378608 hasRelatedWork W2062901722 @default.
- W2122378608 hasRelatedWork W2164190251 @default.
- W2122378608 hasRelatedWork W2297218150 @default.
- W2122378608 hasRelatedWork W2413498750 @default.
- W2122378608 hasRelatedWork W2537134414 @default.
- W2122378608 hasVolume "62" @default.
- W2122378608 isParatext "false" @default.
- W2122378608 isRetracted "false" @default.
- W2122378608 magId "2122378608" @default.
- W2122378608 workType "article" @default.